Compare 8x8 Inc (EGHT) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs McKesson Corporation — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 347.7× 8x8 Inc's market cap, and McKesson Corporation pays a 0.4% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and McKesson Corporation for 74 Days on average.
| EGHT | MCK | |
|---|---|---|
Market Cap | $311.98M | $108.46B |
Volume | 1,639,086 | 712,607 |
Sector | Technology | Health |
52-Week High | $2.76 | $995.69 |
52-Week Low | $1.59 | $725.17 |
Typical Hold Time | 16 Days | 74 Days |
Enterprise Value | $578.90M | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.13, down 0.47% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with $715M in 2025 and positive earnings beats in recent quarters, though profitability remains challenged with a net loss of $27M. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus is mixed with a $19.77 price target representing significant upside potential.
EGHT presents a high-risk, high-reward opportunity with substantial analyst upside but faces execution risks amid competitive pressures. The stock's current valuation at 72x P/E reflects growth expectations, but investors must weigh the company's debt load and margin challenges against its strategic positioning in cloud communications and AI innovation.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
